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Abstract
Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often arising in histologically 
advanced disease when steatohepatitis is not active (cryptogenic cirrhosis). Our objective was to characterize patients with HCC 
and active, histologically defined steatohepatitis. Among 394 patients with HCC detected by ultrasound imaging over 8 years 
and staged by the Barcelona Clinic Liver Cancer (BCLC) criteria, we identified 7 cases (1.7%) with HCC occurring in the setting 
of active biopsy-proven NASH. All were negative for other liver diseases such as hepatitis C, hepatitis B, autoimmune hepatitis, 
Wilson disease, and hemochromatosis. The patients (4 males and 3 females, age 63 ± 13 years) were either overweight (4) 
or obese (3); 57% were diabetic and 28.5% had dyslipidemia. Cirrhosis was present in 6 of 7 patients, but 1 patient had well-
differentiated HCC in the setting of NASH without cirrhosis (fibrosis stage 1) based on repeated liver biopsies, the absence 
of portal hypertension by clinical and radiographic evaluations and by direct surgical inspection. Among the cirrhotic patients, 
71.4% were clinically staged as Child A and 14.2% as Child B. Tumor size ranged from 1.0 to 5.2 cm and 5 of 7 patients were 
classified as early stage; 46% of all nodules were hyper-echoic and 57% were <3 cm. HCC was well differentiated in 1/6 and 
moderately differentiated in 5/6. Alpha-fetoprotein was <100 ng/mL in all patients. HCC in patients with active steatohepatitis is 
often multifocal, may precede clinically advanced disease and occurs without diagnostic levels of alpha-fetoprotein. Importantly, 
HCC may occur in NASH in the absence of cirrhosis. More aggressive screening of NASH patients may be warranted.
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Non-alcoholic fatty liver disease (NAFLD) is a clinical 
and pathological condition whose spectrum can range from 
steatosis to steatohepatitis and cirrhosis in patients without 
a history of alcohol abuse (1). Non-alcoholic steatohepatitis 
(NASH), the severe form of NAFLD, has emerged as a 
clinically important type of chronic liver disease character-
ized pathologically by hepatocellular ballooning, Mallory’s 
hyaline, scattered inflammation, and perisinusoidal fibrosis 
(2). NASH associated with cirrhosis progresses to hepa-
tocellular cancer and reoccurs post-transplantation (3,4). 
This disorder is now considered to be the major cause of 
cryptogenic cirrhosis in many regions of the world (5). 
More recently, NASH has been increasingly associated 
with hepatocellular carcinoma (HCC), often arising in the late 
stage of the disease with non-specific histology ascribed to 
cryptogenic cirrhosis (6). Thus, NASH-related HCC is often 
thought to occur primarily in patients with advanced disease, 
when hepatocellular ballooning, inflammation and steatosis 
(e.g., NASH) have subsided. For example, Marrero et al. (7) 
studied the etiology of liver disease in 150 patients with HCC 
wherein NAFLD-related cryptogenic cirrhosis accounted for 
at least 13% of the cases. However, fibrosis progression in 
NAFLD appears to be typically slow (8,9) and the clinical 
features of HCC arising in earlier stages of NASH are not 
well-defined, although obesity is a recognized risk factor 
for both NASH and HCC (10) and sporadic cases of HCC 
arising from non-cirrhotic NAFLD have been reported (11). 
The aim of this study was to characterize patients with HCC 
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and histologically defined NASH with or without cirrhosis. 
Patients and Methods
Patients
Between April 1998 and August 2006, 394 consecutive 
patients with HCC were evaluated at a single center (Depart-
ment of Gastroenterology of Clinic Hospital of University 
of São Paulo School of Medicine). According to etiology, 
hepatitis C virus was the most frequent in 58%, followed 
by hepatitis B virus in 16%, alcohol in 10% and cryptogenic 
disease in 9%. We identified 7 patients (1.7%) with histo-
logically proven NASH. Six of 7 associated hepatocellular 
cancers were confirmed histologically. The protocol was 
approved by the Internal Review Board of the University 
of São Paulo (São Paulo, SP, Brazil).
Diagnostic criteria
The diagnosis of NASH was based on the following criteria: 
1) a liver biopsy specimen showing steatosis (>10% of hepa-
tocytes), hepatocellular ballooning and pericellular fibrosis as 
assessed by a liver pathologist with expertise in NAFLD; 2) 
the exclusion of liver diseases such as hepatitis B, hepatitis 
C, autoimmune hepatitis, alpha1-antitrypsin deficiency, Wilson 
disease, and hemochromatosis; 3) the exclusion of patients 
who had a >100 g/week alcohol intake determined by a detailed 
personal history, questioning of family members, and an inves-
tigation of previous medical records, and 4) the exclusion of 
patients with steatohepatitis accompanying other liver diseases, 
or systemic diseases other than obesity, hyperlipidemia, and 
diabetes or with an intake of hepatotoxic drugs or lipid-lowering 
agents. HCC diagnostic criteria included coincident findings by 
at least two imaging techniques showing characteristic features 
in a focal hepatic lesion >2 cm, with arterial hypervasculariza-
tion (Barcelona Clinic Liver Cancer (BCLC) criteria) (12) and 
histologically confirmed in 6 of 7 patients. 
Laboratory assays
Laboratory examinations included tests for hepatitis B 
surface antigen, hepatitis B surface antibody (anti-HBs), 
hepatitis B core antibody (anti-HBc) by enzyme immunoas-
say (Dinabot, Japan), HCV antibody by third-generation en-
zyme immunoassay (Ortho Diagnostics, Japan), HCVRNA 
by the polymerase chain reaction (Amplicor HCV, Roche 
Diagnostic Systems, Japan), anti-nuclear antibody and 
anti-smooth muscle antibody by immunofluorescence on 
Hep 2 cells. Tests for alpha-fetoprotein (AFP) were done 
by EIA. Aminotransferase studies and other routine tests 
were performed by standard methods using automated 
techniques (Modular P800, Roche/Hitachi, Switzerland). 
Histology
The liver tissue was fixed in 4% formaldehyde and 
processed for hematoxylin-eosin, Masson trichrome and 
picrosyrius red stains, Gomori’s silver impregnation for 
extracellular matrix and Perls staining for pigments. All 
specimens were scored blindly for individual histological 
parameters by a liver pathologist with expertise in NAFLD: 
macro- and microvacuolar fatty change, zonal distribu-
tion, foci of necrosis, portal and perivenular fibrosis, and 
inflammatory and fibrotic infiltrate with zonal distribution 
and the composite NASH activity score were calculated 
(13). Fibrosis was assessed using a 4-grade scale. In this 
scheme, F1 denotes foci of perivenular/pericellular fibrosis 
in zone 3, F2 represents the changes defining F1 plus 
focal or extensive periportal fibrosis, F3 denotes bridging 
fibrosis (focal or widespread), and F4 indicates the pres-
ence of cirrhosis. The grade of tumor differentiation was 
assessed as best differentiated (grade I), well differentiated 
(grade II), moderately differentiated (grade III), or poorly 
differentiated (grade IV), according to the Edmonson & 
Steiner classification. 
Results 
There were 4 males and 3 females with a mean age of 
63 ± 13.9 years. Four patients (5%) were overweight (BMI 
25-29.9 kg/m2) and 3 were obese (BMI ≥30) (43%); 57% had 
type II diabetes and 28.5% had dyslipidemia. Cirrhosis was 
present in 6 of the 7 patients (Figure 1A) and 1 had HCC 
and NASH without cirrhosis, with a liver biopsy showing 
only perivenular and pericellular fibrosis (stage 1; Figure 
1B,C). Clinical and radiologic parameters confirmed the 
absence of evidence of portal hypertension in this patient 
(see details below). Among the cirrhotic patients, 71.4% 
were clinically staged as Child A and 14.2% as Child B. 
Lesions were visualized by ultrasound in all patients. These 
data are summarized in Table 1. 
Four patients had only one HCC nodule, 1 patient had 
2 tumors, 1 patient had 3 tumors, and 1 had 4 tumors 
(Table 1). Tumor size ranged from 1.0 to 5.2 cm and 8 of 
14 nodules (57%) were <3 cm. Most lesions (46%) were 
hyper-echoic by ultrasound. The HCC was well differentiated 
in 2/6 (33.3%; Figure 1D,E), moderately differentiated in 
4/6 (66.6%; Figure 1F) and poorly differentiated in none. An 
interesting finding was the presence of histological features 
of NASH in 4 of 7 cases. In several neoplastic cells, we 
observed focal to moderate steatosis (Figure 1E,F), balloon-
ing and Mallory bodies (Figure 1F). In 2 cases, we found 
also peliosis. These intracellular lesions were apparently 
associated with milder histological grades. AFP was <100 
ng/mL in all patients (Table 1). 
HCC in NAFLD in the absence of cirrhosis
A 65-year-old asymptomatic male was found to have 
increased aminotransferase values during his annual physi-
cal examination. Ultrasound revealed two liver nodules. He 
had a history of hypertension, hyperlipidemia and hyperu-
ricemia. His medical history was otherwise unremarkable. 
He was overweight (BMI, 27.6/m2) without signs of chronic 
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Figure 1. Microscopic features of non-neoplastic areas and of hepatocellular carcinoma (HCC). A, Hepatic cirrhosis with thin septae 
(arrows). Prominent hepatocellular ballooning (arrowheads) is seen together with Mallory bodies. Grade I steatosis and scarce polymor-
phonuclear and lymphocytic inflammation (case 3, HE, 200X). B, Steatohepatitis stage 1 contralateral to HCC. An individualized portal 
tract shows minimal inflammation and no fibrosis (arrow). Steatosis is seen in 15-20% of hepatocytes (arrowheads, case 6, HE, 100X). 
C, Another microscopic field of the same case, presenting a preserved terminal (centrilobular) venule, surrounded by steatotic hepato-
cytes. Some polymorphonuclears are found (case 6, HE, 200X). D, Well-differentiated HCC presenting small hepatocytes crowded in 
thin trabeculae in the non-alcoholic steatohepatitis (NASH) case without cirrhosis (case 6, HE, 100X). E, Well-differentiated HCC show-
ing micro- and macrogoticular steatosis (case 7, HE, 100X). F, Moderately differentiated HCC presenting features of NASH: ballooning 
(arrows) and Mallory bodies (arrowhead) are found in neoplastic cells (case 2, HE, 400X). G, Computed tomographic scan indicating a 
steatotic liver with a hypervascular mass in segment 3. H, Intraoperative view of a non-cirrhotic liver with a tumor located in segment 3.
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liver disease. Using ultrasound, computed tomography, and 
magnetic resonance imaging, we detected two hypoechoic 
tumors measuring 52 mm in the greatest dimension in 
segment II and 10 mm in segment V, and steatosis in the 
background, without signs of cirrhosis or portal hypertension 
(Figure 1G,H). An ultrasound-guided biopsy from the largest 
nodule showed a grade-I trabecular HCC (Figure 1D). The 
non-cancerous areas showed NASH stage 1, characterized 
by minimal perivenular fibrosis, moderate steatosis with 
mild hepatocellular ballooning and mild necroinflamma-
tion (Figure 1C). Portal tracts were normal-sized, without 
fibrous septa (Figure 1B). Therefore, surgical resection (left 
hepatectomy) for the segment 2 lesion was indicated and 
at the time of surgery radioablation of the tumor in segment 
V was planned. However, since intra-operatory ultrasound 
showed 12 nodules, both in the right and in left hepatic 
lobes, it was decided not to do any hepatic resection or 
radioablation. The macroscopic liver aspect on surgery 
revealed only steatosis, without signs of cirrhosis or portal 
hypertension. The patient was therefore intra-operatively 
submitted again to a liver and tumor biopsy. 
The histological findings confirmed a diagnosis of grade I 
HCC and underlying NASH stage 1, without cirrhosis. The pa-
tient was treated with transcatheter arterial chemoembolization. 
He is alive without symptoms, 24 months after diagnosis. 
Discussion 
Hepatocellular carcinoma is a well-recognized end-point 
of the progression of NASH although the exact risk remains 
to be defined. In recent years, NASH has been proposed 
as an important cause of HCC especially in industrialized 
countries where obesity rates and associated fatty liver 
disease have become a common problem. However, most 
cases have been found in the setting of cryptogenic cirrhosis 
thought to be due to progression of NASH. In the present 
paper, we describe 7 cases of HCC in histologically defined 
NASH patients including one case without cirrhosis. 
The clinical features of NASH patients with HCC studied 
herein differ in some respects from those of HCC patients 
with cirrhosis associated with HCV or HBV infection. In the 
series of 93 cirrhotic patients who developed HCC during 
the screening program in our group (Campos-Cella LT, 
Paranagua-Vezozzo DC, Farias AQ, Ono-Nita SK, Matielo 
CH, Alves VAF, et al., unpublished data), we found that 
57 years was the average age of patients with HCC. In 
the present study of NASH patients, the mean age was 
considerably higher with an average of 63 years, similar 
to a previous study reporting later HCC development in 
patients with NASH (14).
The most important factors for the development of HCC 
in most literature reports were hepatitis B and C infections. 
In the present series, viruses were ruled out in patients 
with a background of overweight in all cases, 57% of the 
patients had non-insulin-dependent diabetes mellitus and 
28.5% had dyslipidemia. Obesity itself is a recognized risk 
factor for both NASH and HCC (10) and isolated cases of 
HCC arising from non-cirrhotic NAFLD have been reported 
(11). In our series, there was 1 patient of 7 with non-cirrhotic 
NASH who was obese.
The histological features of NASH complicated by HCC 
were somewhat different from HCC associated with other 
cirrhotic causes. The livers were cirrhotic in 6 patients and 
non-cirrhotic in 1 patient and the histological characteristics 
Table 1. Demographic, clinical, biochemical, and histological parameters of the 7 patients studied.
1 2 3 4 5 6 7
Gender F M M M F M F
Age (years) 59 71 61 77 35 65 73
Diabetes mellitus Y Y N N Y N Y
Overweight Y Y Y Y Y Y Y
Dyslipidemia N Y N N N Y N
Cirrhosis Y Y Y Y Y N Y
Child-Pugh A6 A5 A5 A5 B9 - A6
AFP (ng/mL) 6 10 21 10 3 7 17
HCC Rx TACE Resection PEI + TX Resection TACE TACE PEI
HCC differentiation NA GII GII GIII NA GI GI
Number of nodules 1 1 3 1 4 2 1
Echo pattern High High High NA Low Mixed High
HCC size (mm) 33 34 30 43 28 52 33
Stage (BCLC) Early Early Early Early Intermediate Intermediate Early
AFP = alpha-fetoprotein; HCC = hepatocellular carcinoma; TACE = transcatheter arterial chemoembolization; PEI + TX = percu-
taneous ethanol instillation + liver transplantation; NA = not available by ultrasound; GI, II, III = grades I, II and III, respectively; 
BCLC = Barcelona Clinic Liver Cancer criteria.
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of HCC showed a predominance of well to moderately differ-
entiated HCC, similar to previously reported data regarding 
NASH-related HCC (15). No case of undifferentiated HCC 
was detected. Intriguingly, morphologic features of NASH 
such as fatty change, ballooning and Mallory bodies were 
observed in neoplastic hepatocytes, a fact that must be 
further studied in prospective series. All patients studied 
herein had been selected for presenting histological fea-
tures of non-alcoholic steatohepatitis in liver parenchyma 
distant from the tumor.
The pathogenesis of HCC in NASH remains uncer-
tain, although cirrhosis itself may be seen as a promoter 
of neoplastic transformation. However, the finding of one 
case of HCC in the absence of relevant fibrosis or cirrhosis 
shows that cirrhosis is not mandatory for HCC appearance 
in NASH patients. The mechanisms of pathogenesis of 
HCC in the non-fibrotic liver have not been elucidated. 
NASH-associated insulin resistance causes inhibition of 
hepatic mitochondrial fatty acid oxidation and increased 
intracellular fatty acids may lead to oxidative DNA damage 
by stimulating microsomal peroxidases. 
Another interesting aspect differed from the results 
reported by Iannaccone et al. (16), i.e., most patients were 
classified as early stage according to the BCLC staging 
system and most of them were uninodular and smaller 
than 5 cm. This discrepancy may be due to the fact that, in 
our service, patients are submitted to screening programs 
with serum AFP and ultrasound every 6-12 months. The 
non-cirrhotic patient discovered a multinodular HCC in a 
routine ultrasound. The fact that, although multinodular, 
the tumor was so well-differentiated also requires further 
study to search for a possible carcinogenic pathway for 
this intriguing case. 
Cancer in our NASH patients preceded clinically ad-
vanced disease, occurred with non-diagnostic levels of 
AFP and can be diagnosed in the early stage in a screen-
ing program. Moreover, the association of NASH with HCC 
is not limited to patients with NASH-related cirrhosis. We 
observed HCC in 1 of 7 patients without cirrhosis by multiple 
parameters including repeated biopsy, radiographic imag-
ing and direct surgical inspection. Further investigation of 
these relationships is warranted to determine relative risk 
and the possible need for more aggressive screening in 
NASH patients. 
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